Toronto Dominion Bank Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Toronto Dominion Bank lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 15.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,929 shares of the company’s stock after buying an additional 2,408 shares during the quarter. Toronto Dominion Bank’s holdings in AstraZeneca were worth $1,397,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AZN. McClarren Financial Advisors Inc. lifted its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Hobbs Group Advisors LLC acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at about $35,000. Finally, Groupama Asset Managment grew its stake in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $66.23 on Tuesday. The stock has a market capitalization of $205.35 billion, a P/E ratio of 31.69, a P/E/G ratio of 1.19 and a beta of 0.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company’s fifty day moving average is $69.96 and its two-hundred day moving average is $76.64.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 earnings per share. On average, sell-side analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.